A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

ClinicalTrials.gov ID: NCT00264537

Public ClinicalTrials.gov record NCT00264537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate, as compared to methotrexate alone in rheumatoid arthritis subjects who have not been previously treated with methotrexate.

Study identification

NCT ID: NCT00264537
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Centocor, Inc.; Industry
Enrollment: 637 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2005 (Type not available)
Primary completion: Apr 2008 (Actual)
Completion: Jun 2012 (Actual)
Last update posted: Sep 5, 2014

2005 – 2012

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 18

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Mobile	Alabama	—	—
Not listed	Upland	California	—	—
Not listed	Jacksonville	Florida	—	—
Not listed	Miami	Florida	—	—
Not listed	Coeur d'Alene	Idaho	—	—
Not listed	Moline	Illinois	—	—
Not listed	Springfield	Illinois	—	—
Not listed	Kansas City	Kansas	—	—
Not listed	Witchita	Kansas	—	—
Not listed	Saint Paul	Minnesota	—	—
Not listed	Kansas City	Missouri	—	—
Not listed	Lincoln	Nebraska	—	—
Not listed	Charlotte	North Carolina	—	—
Not listed	Duncansville	Pennsylvania	—	—
Not listed	Dallas	Texas	—	—
Not listed	Fort Worth	Texas	—	—
Not listed	Lubbock	Texas	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00264537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 5, 2014 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00264537 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →